FDI in pharma: Cabinet clears KKR investments in two Indian drug firms

Union health and commerce ministries have been opposing such investment without safeguards for acquisition of domestic critical care pharma firms

 
By Kundan Pandey
Last Updated: Monday 17 August 2015

Gland Pharma laboratory. The company specialises in generic injectable drugs (photo courtesy Gland Pharma)The UPA government took a major investment decision in its final meeting on Tuesday even as the 2014 election verdict is awaited later in the week. The Prime Minister Manmohan Singh-led cabinet cleared foreign investment proposals worth Rs 1,400 crore by private equity major KKR Floorline Investments PTE Ltd in two Indian pharmaceutical companies.
 
According to rough estimates, the two deals are worth over Rs 1,420 crore.

After the Cabinet clearance, KKR Floorline Investments PTE Ltd, a Singapore based company, will acquire 37.98 per cent of the fully diluted equity share capital of Gland Pharma Limited and also 24.9 per cent of the fully diluted equity share capital of Gland Celsus Bio Chemicals Private Limited. Hyderabad-based Gland Pharma is a manufacturer of generic injectable drugs, especially for cardiovascular and orthopaedic patients.

KKR Floorline, which is controlled by KKR & Co, is an investment holding company with no operations at present while Gland Pharma is engaged in the business of production and marketing of specialised injectable formulations of generic versions of drugs.
 
This is the significant development in the pharmaceutical sector due to tussle between few ministries on the norms of foreign direct investment (FDI). Union Ministry of Health and Family Welfare (MoHFW) and Ministry of Commerce have been demanding lower cap on FDI in drug making units. These ministries were also demanding various safeguards for acquisition of domestic critical care pharma companies by multinational firms.

However, Union Ministry of Finance has been supporting faster clearance, that too without any change in norms. The ministry has argued that any such step may send wrong signals to investors.

Competition Commission of India (CCI) had given its green signal to the proposed deal between KKR and Gland Pharma in January and said that the deal does not raise anti-competitive concerns.


Report: How India can attract more foreign direct investment, create jobs, and increase GDP:  The benefits of respecting the intellectual property rights of  foreign pharmaceutical producers

Feature: Implications of drug price competition and Patent term Restoration Act (DPCPTRA) on Indian pharma industry

Feature: Multinationals and monopolies - Pharmaceutical industry in India after TRIPS

Subscribe to Weekly Newsletter :
Related Stories

Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.